Merck Ethics Study In developing a drug to combat river blindness‚ pharmaceutical company Merck discovered an opportunity to treat millions of affected peoples around the world that probably would never see commercial use. The drug in development‚ ivermectin‚ was unaffordable to the primary victims of river blindness‚ Third World peoples. Thus‚ Dr. Vagelos‚ the head of research at the time‚ treaded upon a ethical quagmire; he could either choose to scrap the drug and its further research or
Premium Ethics Philosophy of life Person
Jim Mesplie MBA 519 – Competitive Strategy Case Analysis #4 FACTS Beginning as a small scale manufacturer of chemical in the United States‚ Merck Research Labs (MRL) became the top notch research institution in the pharmaceutical industry by World War II. By attracting the top talent in chemistry‚ biology‚ and pharmacology‚ MRL emerged as the leader in human pharmaceuticals with the release of highly necessary drugs to treat infections‚ and tuberculosis. MRL focused their strengths on three
Premium Generic drug Pharmacology Pharmaceutical industry
Statement of the Problem Merck & Co.‚ Inc.‚ a leading pharmaceutical company‚ faces the threat of the patents of its most popular drugs expiring in 2002. The only way to counter the loss of sales from these drugs going off patent is to develop new drugs in order to refresh the company’s portfolio. LAB Pharmaceuticals‚ a small pharmaceutical company who specializes in the treatment of neurological disorders‚ has approached Merck with the opportunity to license Davanrik‚ a new drug with the potential to
Premium Patent Pharmacology Pharmaceutical drug
CASE 5.1: MERCK ACQUISITION OF MEDCO Abstract Corporate mergers and acquisitions (M&A) have become popular across the globe during the last two decades due to globalization‚ liberalization‚ technological developments‚ and competitive business environment (Fisher & Siburg‚ 2009). The synergistic gains from M&A may result from efficient management‚ economies of scale‚ profitable use of assets‚ exploitation of market power‚ and the use of complementary resources (Mitchell
Premium Pharmacology Pharmaceutical industry Pharmacy
Licensing Parents Hugh Lafollette Lafollette’s thesis and argument is that we should require all parents or potential parents to procure a license prior to having children. Just as we have licensing programs for anything potentially very harmful today‚ we should also have one for being a parent. We license drivers‚ doctors‚ gun owners‚ and many other types of potentially harmful practices. So why shouldn’t we also license parents? Hugh’s argument is structured as this: P1: Any practice or
Premium Child abuse Abuse License
a) Introduction in 1999 b) Withdrawal of the drug in 2004 due to heart attacks c) Merck’s knowledge of the effects of Vioxx and unethical decision to continue to sell the drug 2) Vigor Study d) Vioxx lessened stomach bleeding e) Results also showed higher risk of heart attacks f) Merck blamed naproxen for skewing the results against Vioxx 3) New England Journal of Medicine Omission g) Merck omits three heart attacks from article submission
Premium Coronary artery disease Aspirin Hypertension
Executive Summary Merck & Company has been presented with an opportunity to invest $30 million for the purchasing rights of an obesity and high cholesterol lowering drug‚ KL-798 from Kappa Labs. Based on the expected probabilities of success through each product-development phase for this new drug‚ as well as the costs involved‚ the net present value of the project is -$1.16 million and is therefore recommended that Merck passes on the investment. Sensitivity analysis also show that adjusting
Premium Clinical trial Net present value Investment
Pharmaceuticals: Merck Sustaining Long-term Advantage Through Information Technology Hiroshi Amari Working Paper No. 161 Working Paper Series Center on Japanese Economy and Business Columbia Business School December 1998 Columbia-Yale Project: Use of Software to Achieve Competitive Advantage PHARMACEUTICALS: MERCK Sustaining Long-term Advantage Through Information Technology Prepared by Hiroshi Amari Research Associate‚ Yale University William V. Rapp and Hugh T. Patrick Co-principal
Premium Clinical trial Pharmaceutical industry Drug development
BUAD820 – Case 2 Merck Case Decision Tree and Analysis Presented By – Sridevi Chennuri Nuray Coban Subhashini Reddy Merck & Company :Evaluating a Drug Licensing Opportunity • Background - Merck & Company : •In 2000‚ it was a global research-driven pharmaceutical company that discovers‚ develop‚ manufactures and markets a broad range of human and animal health products‚ directly and through its joint ventures‚ and provides pharmaceutical benefit management services through Merck-Medco Managed Care
Premium Clinical trial Decision tree Expected value
TO: Dr. Roy Vagelos‚ Chairman and CEO Merck Corporation. January‚ 1991. The decision to move forward with the program to donate the new drug Mectizan on a large scale to the affected population in the Third World needs to be systematically analyzed. There are two especially important angles from which this decision needs to be considered. The first concern that needs to be taken into account is that of the stockholders and investors in this company‚ whose interests you are ultimately charged with
Premium Medicine Pharmacology Pharmacy